News from Novella, MicroConstants and Cromos Pharma – People on the move
We begin this week with news from Novella Clinical with two new Directors of Client Business Development in the forms of Carole Gabos and Jeremie Braun. They will be working to enhance Novella’s west coast business.
Gabos is rejoining Novella having worked with the CRO in the early 2000s and has over 20 years of experience with both small and large CROs.
Braun comes to the company with over ten years in sales at biopharma companies.
Novella Clinical Executive Vice President Nick Dyer said: “The addition of Carole and Jeremie will help us to capture even more of the clinical trial outsourcing market and help bring valuable compounds through the development process.”
Moving from coast to coast, San Diego CRO MicroConstants has hired Pat deLisio as Director of its East Coast Business Development.
With more than 12 years of experience selling contract research services, Pat has worked at several bioanalytical and toxicology CROs throughout the United States and has also spent more than three years as an independent GLP quality assurance consultant.
MicroConstants' President Gilbert Lam said: “Pat’s extensive knowledge of the pharmaceutical development process and her experience establishing and securing new customer opportunities will be a tremendous asset to MicroConstants’ business development team as we focus on enhancing our presence in key geographic regions on the east coast.”
Further East now and to Russia where CRO Cromos Pharma has appointed Dr. Andrey Bazovoy as its Director of Clinical Operations.
Bazovoy has spent the last 15 years at Quintiles, with his most recent post being Leader of International Clinical Project Managers.
“We are very excited to have Dr. Bazovoy join our growing team,” said Dr. Vladimir Bogin, Cromos Pharma's CEO. “Andrey is one of the most experienced and respected top CRO managers in Central/Eastern Europe.”
DNA sequencing company Personalis has hired Michael Fitzpatrick as Vice President Worldwide Sales.
Fitzpatrick comes direct from Applied Biosciences where he worked for 20 years in positions of increasing authority.
Personalis CEO John West said of Fitzpatrick: “As we look to accelerate the growth in next generation sequencing interpretation and analysis and focus on large market opportunities, he will play a key role in helping us achieve this goal.”
Finally this week, Dr. Lynn Webster, chief medical director of CRI Lifetree and co-founder of Lifetree Clinical Research, has been elected president of the American Academy of Pain Medicine (AAPM).
“Pain affects more people than heart disease, cancer, and diabetes combined,” Webster said. “That means there are vast needs — people needlessly suffering — and as leading experts in pain care, the academy can make a difference.”
